SUSMED, Inc. engages in the development of therapeutic applications. It provides joint development platform for therapeutic applications, and development and sales of clinical trial systems using block chain. It operates through the DTx Products and DTx Platform business segments. The DTx Product segment covers the therapeutic application development. The DTx Platform segment provides general-purpose clinical trial systems and machine learning automatic analysis systems, and supporting DTx development utilizing these system. The company was founded by Taro Ueno on July 31, 2015 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company